India’s pharmaceutical exports grew by 6.8% to $8.10 billion during April–June FY 2026-27 with a steady increase in shipments and a growth momentum across all product segments, according to data released by the Pharmaceuticals Export Promotion Council of India (Pharmexcil).
The country had exported $7.58bn in the corresponding period of the previous financial year.
Export momentum strengthened further in June, with pharmaceutical shipments increasing by 7.13% to $2.81bn, compared with $2.62 billion in June FY26.
June exports were also 6.86% higher than the $2.63bn recorded in May this year, indicating sustained month-on-month momentum and a positive start to the financial year.
The United States remained India's largest pharmaceutical export destination during April–June, followed by Brazil, the United Kingdom, the Netherlands, and France.
The list includes both developed and emerging markets, indicating the geographical spread of India's pharmaceutical exports.
During the quarter, the top 25 export destinations together accounted for nearly 70% of India's pharmaceutical exports, with shipments valued at $5.65bn.
Exports to these 25 countries recorded a year-on-year growth of 5.50% during April–June FY27.
Segment-wise growth
Drug formulations and biologicals continued to lead India’s pharmaceutical exports during the quarter, contributing $5.98bn and accounting for 73.85% of total exports.
The category recorded a growth of 4.14% over the corresponding period last year and continued to dominate India's pharmaceutical exports.
Similarly, bulk drugs and drug intermediates, the second-largest export category, grew by 13.84% to $1.36bn, while vaccine exports emerged as the fastest-growing segment, rising by 35.68% to $390 million. Meanwhile, exports of surgical products also registered healthy growth of 11.95% to $210m during the quarter.
The broad-based growth across product categories reflects sustained global demand for affordable generic medicines and increasing procurement from regulated and emerging markets.
The performance also highlights the country's diversified export portfolio, with multiple product segments contributing to overall export growth.
Export reach
In terms of region-wise exports, NAFTA (North American Free Trade Agreement), Europe, Africa, and Latin America & the Caribbean (LAC) continued to be the key export destinations during the quarter, collectively accounting for nearly 75% of the country's total pharmaceutical exports.
NAFTA remained the largest export market, contributing 34.28% of India's overall pharmaceutical exports,.
Pharmexcil chairman Namit Joshi said, “India’s pharmaceutical export performance demonstrates that the sector continues to combine scale in established markets with growing momentum across a wider set of geographies.
"The United States remains our largest export destination, with shipments valued at $2.50bn and a 30.89% share, while the strong performance of Brazil, the Netherlands, France and several emerging markets reflects the expanding global footprint of Indian pharmaceutical companies.
"The double-digit growth recorded across Europe, Africa, Latin America, ASEAN and South Asia is particularly important in the present global trade environment.
"India must continue consolidating its leadership in generics while building a stronger presence in complex generics, biosimilars, peptides and other innovation-led segments."
